Core Viewpoint - Zhuozheng Medical has successfully transitioned from loss to profit, marking a significant milestone with its listing on the Hong Kong Stock Exchange, showcasing a perfect growth trajectory for a private mid-to-high-end medical enterprise [3][4]. Group 1: Company Overview - Zhuozheng Medical officially listed on the Hong Kong Stock Exchange with a share price set at HKD 59, issuing 4.75 million shares and raising a total of HKD 285 million, with a net amount of HKD 209 million after expenses [3]. - The company has established a service network across 10 economically developed cities in China, operating 19 medical service institutions, including 17 clinics and 2 hospitals [3][4]. Group 2: Financial Performance - The company has shown consistent improvement in financial performance, with revenue increasing from CNY 473 million in 2022 to CNY 959 million in 2024, and gross profit rising from CNY 43.98 million to CNY 226 million during the same period [4]. - Zhuozheng Medical achieved a profit of CNY 80.23 million in 2024, marking its first profitable year, and continued this growth trend in the first eight months of 2025 with revenue of CNY 696 million and a profit of CNY 83.21 million [4]. Group 3: Market Position - According to Frost & Sullivan, Zhuozheng Medical ranks third among private mid-to-high-end comprehensive medical service providers in China, holding a market share of 2.0% based on 2024 revenue [4]. - The company stands out in a highly fragmented industry due to its extensive city coverage and large patient base, ranking first in the number of covered cities and second in patient visits among paid patients as of December 31, 2024 [4].

Core Viewpoint - The company,卓正医疗, is launching a global offering of 4.75 million new shares on the Hong Kong Stock Exchange, aiming to raise approximately HKD 219 million for various strategic initiatives [2][5]. Group 1: Offering Details - The global offering consists of 4.75 million shares, with 4.275 million shares allocated for international offering and 475,000 shares for public offering in Hong Kong [2]. - The price range for the shares is set between HKD 57.70 and HKD 66.60, with a midpoint of HKD 62.15 expected to yield a net fundraising of approximately HKD 219 million after expenses [2]. - The public offering period is from January 29 to February 3, with the final price and allocation results to be announced on February 5, and trading to commence on February 6 [2]. Group 2: Use of Proceeds - The funds raised will be allocated as follows: 35% for building a talent pool and strategic partnerships, 30% for upgrading existing facilities and opening new ones, 25% for acquiring well-performing medical institutions in first and new first-tier cities, and the remaining for working capital [2]. Group 3: Investor Support - The offering has secured support from four cornerstone investors, including Health Vision,金域医学, 明略科技, and Galaxy Dynasty, committing to subscribe for shares totaling approximately USD 1.164 million (around HKD 90.79 million) [3]. - The cornerstone investors' commitments represent about 30.44% of the total offering shares, which could increase to 32.22% if the over-allotment option is fully exercised [4]. Group 4: Company Overview - 卓正医疗 focuses on providing private medical services to affluent individuals, operating 19 medical facilities in major Chinese cities and additional clinics in Singapore and Malaysia [5]. - The company is the third-largest private high-end medical service provider in China, with a market share of 2.0% based on projected 2024 revenue [5]. - Revenue has shown significant growth, increasing from RMB 473 million in 2022 to RMB 959 million in 2024, with a compound annual growth rate of 42.3% [5].

Core Viewpoint - Distinct Healthcare Holdings Limited (卓正医疗控股有限公司) has achieved profitability in 2024 after previously incurring losses, indicating a positive turnaround in its financial performance [4]. Group 1: Company Overview - Established in 2012, Distinct Healthcare focuses on the mid-to-high-end private healthcare market in China, operating 20 medical service institutions across major cities [2]. - As of March 10, 2025, the company has expanded its services to Singapore, with three general clinics [2]. - According to Frost & Sullivan, Distinct Healthcare ranks as the third-largest private mid-to-high-end healthcare service provider in China based on 2023 revenue [2]. Group 2: Patient Metrics - The total number of patients served at Distinct Healthcare's facilities in China increased from 162,393 in 2022 to 242,549 in 2024 [3]. - The total paid patient visits across all services, including online platforms, rose from 529,829 in 2022 to 905,825 in 2024 [3]. - The patient retention rate improved from 75.7% in 2022 to 80.0% in 2024, indicating enhanced customer loyalty [3]. Group 3: Financial Performance - Revenue figures for Distinct Healthcare from 2022 to 2024 were 473 million yuan, 690 million yuan, and 959 million yuan, respectively, reflecting a compound annual growth rate (CAGR) of 42.3% [3]. - The gross profit margin increased from 9.3% in 2022 to 23.6% in 2024, showcasing improved operational efficiency [3]. - The adjusted net loss decreased from 123 million yuan in 2022 to 4.3 million yuan in 2023, with a shift to an adjusted net profit of approximately 10.7 million yuan in 2024 [4]. Group 4: Investment and Valuation - Distinct Healthcare has attracted investments from notable institutions, including Tencent, which holds a 19.39% stake, making it the largest institutional investor [5][4]. - Prior to its IPO, the company's valuation was approximately 510 million USD following its last financing round in 2021 [6].